Paper Details

  1. Home
  2. Paper Details

Impact of elagolix treatment on fatigue experienced by women with moderate to severe pain associated with endometriosis.

Author: AgarwalSanjay K, DiamondMichael P, SnabesMichael C, SolimanAhmed M, SurreyEric S

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Elagolix, an oral GnRH antagonist, significantly reduces fatigue levels in women with moderate to severe endometriosis-associated pain. After 6 months of treatment, fatigue levels decreased from 54%-74% to 29%-43% with elagolix 150mg daily and 14%-29% with elagolix 200mg twice daily, compared with 35%-50% with placebo.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To evaluate the efficacy of elagolix, an oral GnRH antagonist, for the reduction of fatigue in women with moderate or severe endometriosis-associated pain. DESIGN: Randomized, double-blind, multicenter, placebo-controlled phase III trial. SETTING: Clinics. PATIENT(S): A total of 860 wo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.fertnstert.2019.02.031

データ提供：米国国立医学図書館（NLM）

Elagolix: A Potential Solution for Fatigue in Endometriosis

The vast desert of endometriosis research is a challenging terrain, and finding effective treatments that address the diverse symptoms is an ongoing quest. This study, focusing on the field of [gynecology], investigates the impact of elagolix, an oral GnRH antagonist, on fatigue experienced by women with moderate to severe endometriosis-associated pain. The researchers conducted a randomized, double-blind, placebo-controlled phase III trial involving 860 women. The study found that elagolix significantly reduced fatigue levels compared to placebo, with a greater reduction observed in women who experienced clinically meaningful response in their pain symptoms. These findings suggest that elagolix may be an effective treatment for fatigue associated with endometriosis.

Elagolix Shows Promise for Reducing Fatigue

The study provides evidence that elagolix can effectively reduce fatigue in women with moderate to severe endometriosis-associated pain. The [significant reduction in fatigue levels] observed in the study is a promising finding, particularly for women who experience fatigue as a major symptom of their endometriosis. The study emphasizes the need for further research to fully understand the mechanisms underlying this effect and to identify the best strategies for managing fatigue in women with endometriosis.

Managing Fatigue Associated with Endometriosis

If you are experiencing fatigue associated with endometriosis, it is important to discuss your treatment options with your doctor. They can help you understand the different treatment approaches available, including medications, such as elagolix, and lifestyle modifications to manage fatigue. Open communication with your healthcare team is essential for developing a comprehensive treatment plan that addresses your individual needs and goals. Remember, managing fatigue requires a collaborative approach and a commitment to improving your overall well-being.

Dr.Camel's Conclusion

This study offers a glimmer of hope for women experiencing fatigue associated with endometriosis. The findings suggest that elagolix may be an effective treatment option for reducing fatigue, but further research is needed to confirm its long-term benefits and to optimize its use. As a wise camel, I encourage you to seek expert advice and to actively engage in your own healthcare journey.

Date :
  1. Date Completed 2019-12-09
  2. Date Revised 2019-12-17
Further Info :

Pubmed ID

30992150

DOI: Digital Object Identifier

10.1016/j.fertnstert.2019.02.031

Related Literature

Article Analysis
・Effective treatment of endometriosis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.